Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination

References

• Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet 2013; 382:889 - 99; http://dx.doi.org/10.1016/S0140-6736(13)60022-7; PMID: 23618600
   PubMed Web of Science ®Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915 - 27; http://dx.doi.org/10.1056/NEJMoa061741; PMID: 17494925
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al, HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301 - 14; http://dx.doi.org/10.1016/S0140-6736(09)61248-4; PMID: 19586656
   PubMed Web of Science ®Google Scholar
• Who. Human papillomavirus vaccines: WHO position paper. Biologicals 2009; 37:338 - 44; http://dx.doi.org/10.1016/j.biologicals.2009.04.005; PMID: 19525124
   PubMedGoogle Scholar
• World Health Organization. Guidelines to assure the quality, safety and efficacy of recombinant human papilloma virus-like particle vaccines: WHO Press [Internet]. Geneva; 2006. Available from: http://www.who.int/biologicals/publications/trs/areas/vaccines/human_papillomavirus/HPVg%20Final%20BS%202050%20.pdf.
   Google Scholar
• Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004; 321:205 - 16; http://dx.doi.org/10.1016/j.virol.2003.12.027; PMID: 15051381
   PubMed Web of Science ®Google Scholar
• Yeager MD, Aste-Amezaga M, Brown DR, Martin MM, Shah MJ, Cook JC, Christensen ND, Ackerson C, Lowe RS, Smith JF, et al. Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 2000; 278:570 - 7; http://dx.doi.org/10.1006/viro.2000.0674; PMID: 11118379
   PubMed Web of Science ®Google Scholar
• Ferguson M, Wilkinson DE, Zhou T. WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24-25 January 2008, Geneva, Switzerland. Vaccine 2009; 27:337 - 47; http://dx.doi.org/10.1016/j.vaccine.2008.10.062; PMID: 19007840
   PubMed Web of Science ®Google Scholar
• Karem KL, Poon AC, Bierl C, Nisenbaum R, Unger E. Optimization of a human papillomavirus-specific enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2002; 9:577 - 82; PMID: 11986263
   PubMedGoogle Scholar
• Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4:425 - 34; http://dx.doi.org/10.4161/hv.4.6.6912; PMID: 18948732
   PubMed Web of Science ®Google Scholar
• Ferguson M, Heath A, Johnes S, Pagliusi S, Dillner J, Collaborative Study Participants. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer 2006; 118:1508 - 14; http://dx.doi.org/10.1002/ijc.21515; PMID: 16184553
   PubMed Web of Science ®Google Scholar
• Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93:284 - 92; http://dx.doi.org/10.1093/jnci/93.4.284; PMID: 11181775
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al, HPV-010 Study Group. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009; 5:705 - 19; http://dx.doi.org/10.4161/hv.5.10.9518; PMID: 19684472
   PubMed Web of Science ®Google Scholar
• Inglis S, Shaw A, Koenig S. Chapter 11: HPV vaccines: commercial research & development. Vaccine 2006; 24 Suppl 3:S3/99-105.
   Google Scholar
• Combita AL, Touzé A, Bousarghin L, Christensen ND, Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002; 76:6480 - 6; http://dx.doi.org/10.1128/JVI.76.13.6480-6486.2002; PMID: 12050360
   PubMed Web of Science ®Google Scholar
• Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24:Suppl 1 S16 - 22; http://dx.doi.org/10.1016/j.vaccine.2005.09.002; PMID: 16219398
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6:271 - 8; http://dx.doi.org/10.1016/S1470-2045(05)70101-7; PMID: 15863374
   PubMed Web of Science ®Google Scholar
• Mollers M, Vossen JM, Scherpenisse M, van der Klis FR, Meijer CJ, de Melker HE. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. J Med Virol 2013; 85:1379 - 85; http://dx.doi.org/10.1002/jmv.23616; PMID: 23722396
   PubMed Web of Science ®Google Scholar
• Simondon F, Khodja H. Capture-recapture method for estimating misclassification errors: application to the measurement of vaccine efficacy in randomized controlled trials. Int J Epidemiol 1999; 28:113 - 6; http://dx.doi.org/10.1093/ije/28.1.113; PMID: 10195674
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342 - 50; http://dx.doi.org/10.1038/nrc798; PMID: 12044010
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459 - 66; http://dx.doi.org/10.1038/sj.bjc.6603469; PMID: 17117182
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et al, HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161 - 70; http://dx.doi.org/10.1016/S0140-6736(07)60946-5; PMID: 17602732
   PubMed Web of Science ®Google Scholar
• Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003; 10:108 - 15; PMID: 12522048
   PubMedGoogle Scholar
• Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12:959 - 69; PMID: 16085914
   PubMedGoogle Scholar
• Lu WX, Cheng T, Li SW, Pan HR, Shen WT, Chen YX, Zhang T, Zheng Z, Zhang J, Xia NS. [Establishment and application of human papillomavirus type 16 pseudovirions neutralization assay]. Sheng Wu Gong Cheng Xue Bao 2006; 22:990 - 5; PMID: 17168325
   PubMedGoogle Scholar
• Wei MX, Li SW, Huang B, Shen WT, Su YZ, Zhang CH, Gu Y, Du HL, Zhang J, Xia NS. [Production of human papillomavirus type 16 virus-like particles and its immunogenicity]. Bing Du Xue Bao 2009; 25:245 - 50; PMID: 19769155
   PubMedGoogle Scholar
• Xie M, Li S, Shen W, Li Z, Zhuang Y, Mo X, Gu Y, Wu T, Zhang J, Xia N. [Expression, purification and immunogenicity analysis of HPV type 18 virus-like particles from Escherichia coli]. Sheng Wu Gong Cheng Xue Bao 2009; 25:1082 - 7; PMID: 19835152
   PubMedGoogle Scholar